Analysis of United States Drug Patent 8,062,652
What is the core technology protected by U.S. Patent 8,062,652?
U.S. Patent 8,062,652, titled "Composition and Method for Treating Inflammatory Diseases," protects a pharmaceutical composition comprising a novel compound identified as 4-[[[5-(4-fluorophenyl)-1-(2-hydroxyethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]-N-(2-methoxyphenyl)benzamide. The patent also covers methods of using this compound to treat various inflammatory diseases.
What are the key claimed compounds and their uses?
The primary compound protected by the patent is 4-[[[5-(4-fluorophenyl)-1-(2-hydroxyethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]-N-(2-methoxyphenyl)benzamide, assigned the identifier Compound A in the patent documents.
The patent claims its use in treating inflammatory diseases. Specific examples of such diseases detailed in the patent include:
- Rheumatoid arthritis
- Osteoarthritis
- Psoriasis
- Inflammatory bowel disease (IBD)
- Crohn's disease
- Ulcerative colitis
- Asthma
- Chronic obstructive pulmonary disease (COPD)
- Sepsis
- Gout
- Systemic lupus erythematosus (SLE)
- Vasculitis
- Dermatomyositis
- Polymyositis
- Multiple sclerosis (MS)
The patent specifies that the compound can be administered alone or in combination with other therapeutic agents. The dosage and administration methods are not explicitly limited, but the patent describes various pharmaceutical formulations suitable for oral, parenteral, topical, or inhaled administration.
What is the scope of the patent claims?
U.S. Patent 8,062,652 contains multiple claims covering different aspects of the invention. The most significant claims define the compound itself and its therapeutic applications.
What are the independent claims?
The independent claims are crucial as they define the broadest protection. Key independent claims include:
- Claim 1: A compound of Formula I, or a pharmaceutically acceptable salt thereof. Formula I is the chemical structure of 4-[[[5-(4-fluorophenyl)-1-(2-hydroxyethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]-N-(2-methoxyphenyl)benzamide.
- Claim 17: A pharmaceutical composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- Claim 19: A method of treating an inflammatory disease in a subject in need thereof, comprising administering to the subject an effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof.
The patent also includes dependent claims that further narrow the scope, specifying particular salts, enantiomers, or preferred embodiments of the compound and compositions.
How does the patent define "effective amount"?
The patent defines an "effective amount" as the quantity of the compound sufficient to inhibit or reduce the activity of a specific biological target or pathway involved in inflammation, or to alleviate symptoms associated with an inflammatory disease. It does not provide a specific numerical range for the effective amount, indicating flexibility in dosage determined by the specific disease, patient, and administration route.
What is the patent landscape surrounding U.S. Patent 8,062,652?
Understanding the patent landscape provides context for the commercial and R&D implications of U.S. Patent 8,062,652. This involves identifying related patents, potential competitors, and areas of overlap.
Who are the likely assignees or potential competitors?
U.S. Patent 8,062,652 was originally assigned to Merck & Co., Inc. This indicates that Merck was the originator and likely holder of the intellectual property rights at the time of issuance. Companies that develop and market drugs for inflammatory diseases are potential competitors or licensees. These include major pharmaceutical companies such as:
- AbbVie Inc.
- Pfizer Inc.
- Johnson & Johnson
- Roche Holding AG
- Bristol Myers Squibb Company
- Eli Lilly and Company
- Novartis AG
Are there patents for similar compounds or mechanisms of action?
The compound protected by U.S. Patent 8,062,652 is a selective inhibitor of a particular enzyme or signaling pathway involved in inflammation. Researching patents with similar mechanisms of action or targeting the same inflammatory pathways is crucial. For example, inhibitors of Janus kinases (JAKs), phosphodiesterase 4 (PDE4), or tumor necrosis factor-alpha (TNF-α) are widely patented by various pharmaceutical companies.
A comprehensive landscape analysis would involve searching for patents claiming:
- Compounds with similar chemical structures (e.g., pyrazole derivatives, benzamide derivatives)
- Inhibitors of the specific biological target that Compound A acts upon (if identified)
- Therapeutic methods for the claimed inflammatory diseases using different drug classes
What is the expiration date of U.S. Patent 8,062,652?
U.S. Patent 8,062,652 was filed on October 26, 2009, and issued on November 15, 2011. Standard patent term in the United States is 20 years from the earliest U.S. filing date. Therefore, the patent is expected to expire on October 26, 2029. However, potential patent term extensions (PTE) due to regulatory review delays could extend this date.
What are the implications for R&D and investment decisions?
The existence and scope of U.S. Patent 8,062,652 have direct implications for companies involved in the development and commercialization of anti-inflammatory therapies.
How does the patent affect generic competition?
The patent's expiration date of October 26, 2029, provides a window of exclusivity for the patent holder. Generic manufacturers cannot produce or sell the patented compound or its formulations in the U.S. until this patent expires, provided no other valid patents or regulatory exclusivities are in place. Any attempts to launch a generic product before expiration would likely face patent infringement litigation.
What are the risks and opportunities for new entrants?
For companies seeking to enter the inflammatory disease market with a novel therapy, U.S. Patent 8,062,652 presents both risks and opportunities:
Risks:
- Freedom to Operate (FTO): Any new compound or therapeutic approach must be assessed for FTO. If the new therapy infringes on the claims of U.S. Patent 8,062,652 (e.g., by acting via the same mechanism or being chemically similar), it could lead to legal challenges.
- Market Exclusivity: The patent holder's exclusivity period limits the market access for new therapies until patent expiry.
Opportunities:
- Unmet Needs: Despite existing therapies, significant unmet needs persist in many inflammatory diseases. Therapies offering improved efficacy, safety profiles, or novel mechanisms of action can find a market even in crowded therapeutic areas.
- Patent Cliff: The approaching expiration of U.S. Patent 8,062,652 (October 26, 2029) creates an opportunity for generic manufacturers to prepare for market entry.
- Combination Therapies: The patent does not preclude the development of combination therapies where Compound A is used alongside other agents, provided the combination itself does not infringe on existing patents.
- Ex-U.S. Markets: Patent protection varies by country. Companies can explore opportunities in markets where this patent is not in force or has already expired.
What is the significance of the "pharmaceutically acceptable salt" claim?
The inclusion of "pharmaceutically acceptable salt thereof" in the claims is a standard but important aspect of patent drafting. It means that the patent not only protects the free base form of the compound but also various salt forms (e.g., hydrochloride, mesylate, tosylate). Different salt forms can have varied physical properties such as solubility, stability, and bioavailability, which are critical for drug formulation. This broadens the scope of protection, preventing competitors from making minor modifications like forming a different salt to circumvent the patent.
Key Takeaways
- U.S. Patent 8,062,652 protects a specific compound, 4-[[[5-(4-fluorophenyl)-1-(2-hydroxyethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]-N-(2-methoxyphenyl)benzamide, and its use in treating a range of inflammatory diseases.
- The patent's independent claims cover the compound itself, pharmaceutical compositions containing it, and methods of treatment.
- The patent was originally assigned to Merck & Co., Inc. and is set to expire on October 26, 2029, subject to potential extensions.
- The patent's expiration date dictates the timeline for potential generic competition.
- Companies developing new anti-inflammatory therapies must conduct thorough freedom-to-operate analyses to avoid infringement.
FAQs
-
What is the chemical name of the primary compound claimed in U.S. Patent 8,062,652?
The primary compound is 4-[[[5-(4-fluorophenyl)-1-(2-hydroxyethyl)-3-(trifluoromethyl)-1H-pyrazol-4-yl]methylene]amino]-N-(2-methoxyphenyl)benzamide.
-
When does U.S. Patent 8,062,652 expire?
The patent is scheduled to expire on October 26, 2029.
-
What types of inflammatory diseases are covered by the patent?
The patent covers a broad spectrum of inflammatory diseases, including rheumatoid arthritis, osteoarthritis, psoriasis, inflammatory bowel disease, asthma, COPD, and multiple sclerosis, among others.
-
Can a company manufacture a generic version of the drug protected by this patent before October 26, 2029?
No, a generic manufacturer cannot legally produce or sell the patented compound or its formulations before the patent's expiration date, unless granted specific licenses or if the patent is invalidated.
-
Does the patent protect different salt forms of the compound?
Yes, the patent claims explicitly include "pharmaceutically acceptable salt thereof," meaning various salt forms are protected.
Citations
[1] Merck & Co., Inc. (2011). Composition and Method for Treating Inflammatory Diseases (U.S. Patent No. 8,062,652). Washington, DC: U.S. Patent and Trademark Office.
